Amarantus BioScience Publishes Positive Parkinson's Phase 2a Data in Brain Journal

Posted by Laura Swartz

February 11, 2015 at 9:00 AM

Yesterday, biotechnology company Amarantus BioScience Holdings, Inc. ( AMBS-OTC) announced that the clinical trial results of its Phase 2a study of eltoprazine to treat Parkinson’s disease levodopa-induced dyskinesias (PD-LID) would be published in an upcoming print edition of Brain: A Journal of Neurology.
Read More

Topics: Amarantus

Pressure BioSciences Announces First Sale of Barozyme™ HT48 and Accelerated Marketing

Posted by Laura Swartz

February 10, 2015 at 11:46 AM

This morning, laboratory instrumentation company Pressure BioSciences, Inc. (PBIO-OTC) announced that it had received the first purchase order for one of its newest products, the Barozyme™ HT48 High-throughput System, and had the potential for a second order for the same product. The possible second purchase could come from an existing European customer that has requested a quote.
 
About the Barozyme™ HT48

Read More

Topics: Pressure BioSciences

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic